Library

Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et al.

1 July 2021. doid: 10.1111/bcp.14823

Rissmann R, Zuiker R

View publication

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact